Q1 EPS Forecast for Larimar Therapeutics Cut by Analyst

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Equities research analysts at William Blair lowered their Q1 2025 earnings estimates for shares of Larimar Therapeutics in a research report issued to clients and investors on Monday, December 16th. William Blair analyst M. Minter now anticipates that the company will post earnings of ($0.35) per share for the quarter, down from their prior forecast of ($0.32). William Blair has a “Outperform” rating on the stock. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.16) per share. William Blair also issued estimates for Larimar Therapeutics’ Q2 2025 earnings at ($0.40) EPS, Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.44) EPS, FY2025 earnings at ($1.64) EPS, FY2026 earnings at ($1.81) EPS, FY2027 earnings at ($1.83) EPS and FY2028 earnings at ($0.19) EPS.

Larimar Therapeutics (NASDAQ:LRMR) last posted its quarterly earnings results on Wednesday, October 30th. The company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.13. During the same period in the previous year, the firm earned ($0.21) earnings per share.

LRMR has been the subject of a number of other reports. Oppenheimer began coverage on Larimar Therapeutics in a research report on Wednesday, October 16th. They set an “outperform” rating and a $26.00 target price for the company. Baird R W upgraded shares of Larimar Therapeutics to a “strong-buy” rating in a report on Wednesday, September 4th. Robert W. Baird initiated coverage on shares of Larimar Therapeutics in a report on Wednesday, September 4th. They issued an “outperform” rating and a $16.00 price target for the company. Wedbush initiated coverage on Larimar Therapeutics in a research note on Thursday, October 3rd. They set an “outperform” rating and a $22.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Larimar Therapeutics in a research note on Monday. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $20.43.

Larimar Therapeutics Price Performance

Shares of LRMR stock traded down $0.06 during trading hours on Thursday, hitting $4.10. The stock had a trading volume of 156,845 shares, compared to its average volume of 620,811. The stock has a market capitalization of $261.61 million, a price-to-earnings ratio of -3.57 and a beta of 0.86. The stock’s 50-day moving average price is $7.03 and its two-hundred day moving average price is $7.68. Larimar Therapeutics has a one year low of $3.01 and a one year high of $13.68.

Institutional Trading of Larimar Therapeutics

Several institutional investors have recently modified their holdings of the stock. Quarry LP boosted its stake in Larimar Therapeutics by 966.7% during the 2nd quarter. Quarry LP now owns 8,000 shares of the company’s stock worth $58,000 after purchasing an additional 7,250 shares during the last quarter. Quest Partners LLC lifted its stake in Larimar Therapeutics by 171.1% in the 3rd quarter. Quest Partners LLC now owns 9,183 shares of the company’s stock worth $60,000 after purchasing an additional 5,796 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Larimar Therapeutics in the third quarter valued at approximately $71,000. Intech Investment Management LLC purchased a new position in Larimar Therapeutics during the third quarter worth approximately $85,000. Finally, Thoroughbred Financial Services LLC acquired a new position in Larimar Therapeutics during the second quarter worth $94,000. Institutional investors and hedge funds own 91.92% of the company’s stock.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.